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Sir,
In a recent issue of the American Journal of Human Genetics,
Hwang et al (2003) reported sex difference in cancer risks
among p53 germline mutation carriers from a follow-up study of
56 carriers belonging to seven families from a screening
of 107 kindreds ascertained through patients with childhood soft
tissue sarcoma. We wish to point out that we have reported
such sex difference 3 years ago (Chompret et al, 2000). The
satisfaction for reading a report confirmatory of our work is
mixed by the lack of acknowledgment and discussion of our
contribution.
Our estimation of cancer risk was based on family data
of 295 children treated for a solid tumour at the Institut
Gustave-Roussy in Villejuif (France), and screened for p53
germline mutations. This sample was selected among 2691
children treated for a solid tumour, whose family history was
investigated between 1991 and 1997 through either of the following
criteria: (1) at least one first- or second-degree relative affected
by early-onset cancer (45 years or younger); (2) multiple primary
cancers in the proband regardless of family history. A total
of 17 mutations were found, four of which were de novo mutations,
and the remaining 13 were segregating in the families. Blood
samples were obtained from first-degree relatives and, when a
relative (first- or second-degree or first cousin) was affected by
early-onset cancer (i.e. diagnosed before age 46), from all the
available family members in that branch of the pedigree. An
original method of estimation of cancer risk in carriers (Le Bihan
et al, 1995) that takes into account the particular ascertainment
design of this family sample was used. Cumulative cancer risks by
ages 16, 45 and 85 years were estimated to be respectively 19, 41
and 73% in males, and 12, 84 and 100% in females. There was no
difference between males and females in childhood, with an
average risk of 15%, but the risks were found to be significantly
higher in females than in males in adulthood, and in particular in
the 16–45 age class.
We appreciate that cancer risk estimates, obtained from
informative and a priori free of any ascertainment bias data, by
Hwang et al (2003) are quite similar to ours. The cumulative risks
estimated by these authors by ages 20, 30, 40 and 50 years were,
respectively, 18, 49, 77 and 93% in female carriers, and 10, 21, 33
and 68% in male carriers. The original finding in this study is that
the difference in risk between males and females cannot be
explained by the sex-specific cancer, since the difference remained
after exclusion of breast, ovary and prostate cancer. Furthermore,
they were able to evaluate more accurately the risks at various
tumor sites, which was not possible from our data. Only relative
risks were estimated, although it would have been interesting to
estimate the absolute risks of second cancers, a major issue for
germline p53 carriers.
The comparison of the results of Hwang et al (2003) to our data
allows to draw an interesting conclusion on p53 germline
mutations. Although our study used far less stringent criteria
than those defining the Li–Fraumeni syndrome (Li et al, 1988) for
selecting families, most of the mutations were found in families
with strong familial aggregation, suggesting that low penetrance
mutations are probably rare. These findings are confirmed by the
study of Hwang et al (2003), which, in spite of less stringent
criteria, also finds mutations in families with strong familial
aggregation: 67 malignant tumours were found in 45 individuals in
56 carriers within only seven families. If low-penetrance mutation
was not rare, their estimates of cancer risk would have been lower
than ours, which is not the case.
That penetrance is incomplete in men has an important
implication on the diagnosis of the syndrome. Indeed, if a p53
mutation segregates in a family in which, by chance, most carriers
are males, the classical criteria for diagnosing a Li–Fraumeni
syndrome (Li et al, 1988) are most unlikely to be reached and
looser criteria (Birch et al, 1994; Varley et al, 1997; Chompret et al,
2001) must be preferred.
Editor’s note: When we contacted Dr Louise C Strong, one of the
principle authors on the paper published in the American Journal
of Human Genetics to which Dr Feunteun referred, Dr Strong
kindly replied that she became aware of Dr Feunteun’s prior paper
shortly after her own paper was published and would certainly
have cited it had she been aware of it earlier.
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